Rivaroxaban

證據等級: L5

預測適應症: 4 個

Rivaroxaban: From Anticoagulation Therapy to Rheumatoid Arthritis

One-Sentence Summary

Rivaroxaban is a Factor Xa inhibitor anticoagulant, referenced in the evidence pack primarily for venous thromboembolism (DVT/PE) and atrial fibrillation-related anticoagulation. The TxGNN model predicts it may be effective for Rheumatoid Arthritis, but this prediction is currently supported by 0 directly relevant clinical trials and 4 publications, none of which address RA treatment itself — the literature instead covers VTE management, thrombin generation assays, DOAC adherence, and a case report where RA was only an incidental patient characteristic.

Quick Overview

Item	Content
Original Indication	Not formally recorded (data gap — see DG001/DG002); drug class context in the evidence pack indicates anticoagulant use (e.g., DVT/PE treatment per referenced trial NCT00786422)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.57%
Evidence Level	L5
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap DG002). Based on the mechanistic notes embedded in the evidence pack, rivaroxaban is a direct Factor Xa inhibitor used for anticoagulation. It has no known anti-inflammatory or immunomodulatory activity that would plausibly intervene in the synovitis or autoimmune pathology underlying rheumatoid arthritis.

The retrieved literature does not support a treatment relationship: it consists of a VTE management review, a methodological paper on thrombin generation assays in autoimmune disease, a DOAC adherence comparison in atrial fibrillation, and a perioperative case report in which RA was merely a comorbidity of the patient on oral corticosteroids — none evaluate rivaroxaban as a therapy for RA itself. The most likely explanation for this TxGNN prediction is an indirect network association (RA patients carry elevated thrombotic risk and may require anticoagulation), rather than a genuine disease-modifying mechanism.

Given the absence of a plausible mechanistic link, target-relevant trials, or supportive literature, this prediction should be treated as exploratory only and not advanced without new mechanistic evidence.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29621248	2018	Cohort	PloS one	Compared adherence rates between rivaroxaban and apixaban in non-valvular AF patients; not related to RA treatment.
33141212	2020	Review	JAMA	General review of DVT/PE diagnosis and treatment; no RA content.
34175144	2021	Review	La Revue de medecine interne	Discusses thrombin generation assay as a tool to assess hypercoagulability in autoimmune diseases (e.g., antiphospholipid syndrome); does not evaluate rivaroxaban for RA.
41918541	2026	Case Report	Cureus	Case of thromboembolic stroke in an 88-year-old AF patient with RA on oral steroids; RA is an incidental comorbidity, not a treatment target.

Germany Market Information

No marketing authorization records are available for rivaroxaban in this dataset (market status: Not Marketed, 0 authorizations on file).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data are currently unavailable — see data gap DG001, classified as Blocking, which prevents S1 safety screening.)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted RA indication has no plausible mechanistic basis, no supporting clinical trials, and literature that is entirely off-target; evidence level is L5 (model prediction only). This is consistent with the other three TxGNN-predicted indications for rivaroxaban in this evidence pack (gout, HIV infectious disease, brachydactyly-syndactyly syndrome), all of which are also scored Hold with L4–L5 evidence and no mechanistically relevant support.

To proceed, the following is needed:

TFDA/BfArM label data (warnings, contraindications) to close the Blocking data gap (DG001) before any S1 safety screening can occur
DrugBank-sourced mechanism of action data (DG002) to properly evaluate mechanistic plausibility
If pursuing the RA hypothesis further: preclinical or mechanistic studies directly testing Factor Xa inhibition in RA-relevant pathways (e.g., synovial inflammation models), since current literature only touches on RA as an incidental comorbidity
Formal original indication and licensing data, currently absent from the registry, to properly frame the repurposing rationale
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.